Human Immunodeficiency Virus Type 1 Pharmacogenomics in Clinical Practice: Relevance of HIV-1 Drug Resistance Testing (Part 2)

Journal of Environmental Pathology, Toxicology and Oncology

Volumn 22, Issue 4, 2003, Pages 235-279

  Patarca, Roberto ^a   Isava, Alejandro ^b   Campo, Rafael ^b   Rodriguez, Nelson J ^a   Nunez, Enriqueta ^a   Alter, Michael ^a   Marchette, Margaret ^a   Sanabia, Mirtha M ^a   Mitchell, Charles ^b   Rivera, Delia ^b   Scott, Gwendolyn ^b   Jayaweera, Dushyantha ^b   Moreno, Jose ^b   Boulanger, Catherine ^b   Kolber, Michael ^b   Mask, Cindy W ^c   Sierra, Eduardo Meneses ^d   Vallejo, Ricardo ^e   Page, J Brian ^a   Klimas, Nancy G ^a   Fletcher, Mary Ann ^a   more..

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b JACKSON MEMORIAL HOSPITAL   (United States)

^c Visible Genetics Inc   (United States)

^d Grupo Christus Muguerza   (Mexico)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Antiretroviral treatment; Drug resistance testing; HIV 1; Mutations; Protease; Reverse transcriptase; Viral fitness; Virus infection

Indexed keywords

141 W 94; A 76889; A 77003; AMPRENAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; BENZODIAZEPINE DERIVATIVE; DIDANOSINE; DROXINAVIR; INDINAVIR; KYNOSTATIN 272; LAMIVUDINE; NELFINAVIR; R 0318959; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; SB 203386; SERINE PROTEINASE INHIBITOR; TELINAVIR; UNCLASSIFIED DRUG; ZALCITABINE; ZIDOVUDINE;

ADD ON THERAPY; AMINO ACID SUBSTITUTION; ANTIVIRAL ACTIVITY; CAT DISEASE; CLINICAL PRACTICE; CRYSTAL STRUCTURE; DRUG CROSS REACTIVITY; DRUG MEGADOSE; DRUG POTENCY; DRUG SENSITIVITY; ENZYME INHIBITION; ENZYME SUBSTRATE COMPLEX; FOOD AND DRUG ADMINISTRATION; GENE MUTATION; GENE SEQUENCE; GENETIC ANALYSIS; GENETIC EPISTASIS; GENETIC VARIABILITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYDROPHOBICITY; INFECTION RESISTANCE; INFECTION SENSITIVITY; MEDICAL DECISION MAKING; MOLECULAR INTERACTION; MUTATION RATE; PHAGE DISPLAY; PHARMACOGENOMICS; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN CROSS LINKING; PROTEIN DEGRADATION; PROTEIN DOMAIN; REVIEW; SCREENING TEST; SITE DIRECTED MUTAGENESIS; STRUCTURAL HOMOLOGY; TREATMENT FAILURE; TREATMENT INDICATION; VIREMIA; VIRUS GENE; VIRUS GENOME; VIRUS ISOLATION; VIRUS MORPHOLOGY; VIRUS REPLICATION; VIRUS TRANSMISSION;

ANTIVIRAL AGENTS; CLINICAL TRIALS; DNA MUTATIONAL ANALYSIS; DNA, VIRAL; DRUG RESISTANCE, VIRAL; ENDOPEPTIDASES; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; PHARMACOGENETICS; PHENOTYPE; RNA-DIRECTED DNA POLYMERASE; SEQUENCE ANALYSIS, DNA;

FELIS CATUS; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; RNA VIRUSES;

EID: 0345687873     PISSN: 07318898     EISSN: None     Source Type: Journal    
DOI: 10.1615/JEnvPathToxOncol.v22.i4.10     Document Type: Review

References (339)

1. Osterholm MT. Emerging infections-another warning. N Engl J Med 2000; 342(17):1280-1281.
2. Brazilian Epidemiologic Bulletin on AIDS Year XIII, no. 03-36 to 52 epidemiologic weeks. October to December, 2000.
3. Centers for Disease Control and Prevention. The global HIV and AIDS epidemic 2001. Morbid Mortal Week Rep 2001; 50:434-439.
4. Gayle HD, GL Hill. Global impact of human immunodeficiency virus and AIDS. Clin Microbiol Rev 2001; 14:327-335.
5. Joint United Nations Program on HIV/AIDS. Report on the HIV/AIDS global epidemic. June 2000, Geneva. UNAIDS/0013E (2000).
6. Kamali A, LM Carpenter, JAG Whitworth, R Pool, A Ruberantwari, A Ojiywa. Seven year trends in HIV-1 infection rates and changes in sexual behavior among adults in rural Uganda. AIDS 2000; 14: 427-434.
7. Piot P, M Bartos, PD Ghys, N Walker, B Schwartlander. The global impact of HIV/AIDS. Nature 2001; 410:968-973.
8. United Nations Children's Fund. The progress of nations 2000. New York.
9. Bruguera M, JM Sanchez Tapias. Epidemiology of hepatitis C virus infection. Nephrol Dial Transplant 2000; 15 Suppl 8:12-14.
10. Lauer GM, BD Walker. Hepatitis C virus infection. N Engl J Med 2001; 345(1):41-52.
11. Bennett BK, IB Hickie, US VoUmer-Conna, B Quigley, CM Brennan, D Wakefield, MP Douglas, GR Hansen, AJ Tahmindjis, AR Lloyd. The relationship between fatigue, psychological, and immunological variables in acute infectious illness. Aust N Z J Psychiatry 1998; 32(2):180-186.
12. Sullivan NJ, A Sanchez, PE Rollin, ZY Yang, GJ Nabel. Development of a preventive vaccine for Ebola infection in primates. Nature 2000; 408(6812):605-609.
13. Craven RB, JT Roehrig. West Nile virus. JAMA 2001; 286(6):651-653.
14. Nash D, F Mostashari, A Fine, J Miller, D O'Leary, K Murray, A Huang, A Rosenberg, A Greenberg, M Sherman, S Wong, GL Campbell, JT Roehrig, DJ Gubler, W-J Shieh, S Zaki, P Smith, M Layton for the 1999 West Nile Outbreak Response Working Group. The outbreak of West Nile virus infection in the New York City area in 1999. N Engl J Med 2001; 344(24):1807-1814.
15. Tyler KL. West Nile virus encephalitis in America. N Engl J Med 2001; 344(24):1858-1859.
16. Lindal E, S Bergmann, S Thorlacius, JG Stefansson. Anxiety disorders. A result of long-term chronic fatigue. The psychiatric characteristics of the sufferers of Iceland disease. Acta Neurol Scand 1997; 96(3):158-162.
17. St George IM. Did Cook's sailors have Tapanui flu? Chronic fatigue syndrome on the resolution. N Z Med J 1996; 109(1014):15-17.
18. Buja LM. Does atherosclerosis have an infectious etiology? Circulation 1996; 94:872-873.
19. Danesh J, R Collins, R Peto. Chronic infections and coronary heart disease. Is there a link? Lancet 1997; 350:430-436.
20. Fabricant CG, J Fabricant, MM Litrenta, CR Minick. Virus-induced atherosclerosis. J Exp Med 1978; 148:335-340.
21. Frothingham C. The relation between acute infectious diseases and arterial lesions. Arch Intern Med 1911; 8:153-162.
22. Kullo IJ, GT Gau, J Tajik. Novel risk factors for atherosclerosis. Mayo Clinic Proc 2000; 75:369-380.
23. Libby P, D Egan, S Skarlatos. Roles of infectious agents in atherosclerosis and restenosis. An assessment of the evidence and need for future research. Circulation 1997; 96:4095-4103.
24. Ophüls W. Arteriosclerosis and cardiovascular disease. Their relation to infectious diseases. JAMA 1991; 76:700-701.
25. Atkinson MA, MA Bowman, L Campbell, BL Darrow, DL Kaufman, NK Maclaren. Cellular immunity to a determinant common in glutamate decarboxylase and coxsackievirus in insulin-dependent diabetes. J Clin Invest 1994; 94(5): 2125-2129.
26. Banki K, J Maceda, E Hurley, E Ablonczy, DH Mattson, L Szegedy, C Hung, A Perl. Human T-cell lymphotropic virus (HTLV)-related endogenous sequence HRES-1 encodes a 28-kDa protein. A possible autoantigen for HTLV-I gag reactive autoantibodies. Proc Natl Acad Sci USA 1992; 89(5):1939-1943.
27. Blick M, J Bresser, JL Lepe-Zuniga, A Goodacre, D Luethke, WR Holder, M Duvic. Identification of human immunodeficiency virus hybridizing sequences in the peripheral blood of a patient with systemic lupus erythematosus. J Am Acad Dermatol 1990; 23(4 Pt 1):641-645.
28. Ciampolillo A, V Marini, R Mirakian, M Buscema, T Schulz, R Pujol-Borrel, GF Bottazzo. Retrovirus-like sequences in Graves disease. Implications for human autoimmunity. Lancet 1989; 1(8647): 1096-1110.
29. Dang H, MJ Dauphinée, N Talal, RF Garry, JR Seibold, TA Medsger Jr, S Alexander, CA Feghali. Serum antibody to retroviral gag proteins in systemic sclerosis. Arthritis Rheum 1991; 34(10): 1336-1337.
30. Gama Sosa MA, R De Gasperi, R Patarca, MA Fletcher, EH Kolodny. Antisulfatide IgG antibodies recognize HIV proteins. J Acquir Immune Defic Syndr Human Retrovirol 1997; 15:83-90.
31. Garry RF, CD Fermin, DJ Hart, SS Alexander, LA Donehower, H Luo-Zhang. Detection of a human intracisternal A-type retroviral particle antigenically related to HIV. Science 1990; 250(4894): 1127-1129.
32. Jones DB, NW Armstrong. Coxsackievirus and diabetes revisited. Nature Med 1995; 1:284.
33. Lagaye S, P Vexiau, V Morozov, V Guenebaut-Claudet, J Tobaly-Tapiero, M Canivet, G Cathelineau, J Peries, R Emanoil-Ravier. Human spumaretrovirus-related sequences in the DNA of leukocytes from patients with Graves disease. Proc Natl Acad Sci USA 1992; 89(21):10070-10074.
34. Perl A, PD Gorevic, JJ Condemi, L Papsidero, BJ Poiesz, GN Abraham. Antibodies to retroviral proteins and reverse transcriptase activity in patients with essential cryoglobulinemia. Arthritis Rheum 1991; 34(10):313-318.
35. Silvestris F, RC Williams, F Dammacco. Autoreactivity in HIV-1 infection. The role of molecular mimicry. Clin Immunol Immunopathol 1995; 75:197-205.
36. Talal N, MJ Dauphinée, H Dang, SS Alexander, DJ Hart, RF Garry. Detection of serum antibodies to retroviral proteins in patients with primary Sjögren's syndrome (autoimmune exocrinopathy). Arthritis Rheum 1990; 33(6):774-781.
37. Talal N, RF Garry, PH Schur, S Alexander, MJ Dauphinée, IH Livas, A Ballester, M Takei, H Dang. A conserved idiotype and antibodies to retroviral proteins in systemic lupus erythematosus. J Clin Invest 1990; 85(6):1866-1887.
38. Tian J, PV Lehmann, DL Kaufman. T cell cross-reactivity between coxsackievirus and glutamate decarboxylase is associated with a murine diabetes susceptibility allele. J Exp Med 1994; 180: 1979-1984.
39. Trujillo JR, MF McLane, T-H Lee, M Essex. Molecular mimicry between the human immunodeficiency virus type 1 gp120 V3 loop and human brain proteins. J Virol 1993; 67:7711-7715.
40. Frisch M, RJ Biggar, EA Engels, JJ Goedert for the AIDS-Cancer Match Registry Study Group. Association of cancer with AIDS-related immunosuppression in adults. JAMA 2001; 285(13): 1736-1745.
41. Lederberg J. Infectious history. Science 2000; 288: 287-293.
42. De Kruif P. Microbe Hunters. Orlando FL: Harcourt Brace Jovanovich, 1954.
43. Marwick C. International plan focuses on eradication of polio and containment of the virus. JAMA 2000; 283(12):1553-1554.
44. Haseltine WA, JG Sodroski, R Patarca, D Briggs, D Perkins, F Wong-Staal. Structure of the 3′-terminal region of type II human T-lymphotropic virus. Evidence for a new coding region. Science 1984; 225:419-421.
45. Josephs SF, F Wong-Staal, V Manzari, RC Gallo, JG Sodroski, M Trus, D Perkins, R Patarca, WA Haseltine. Long terminal repeat structure of an American isolate of type I human T-cell leukemia virus. Virology 1984; 139:340-345.
46. Sodroski J, M Trus, D Perkins, R Patarca, F Wong-Staal, E Gelman, RC Gallo, WA Haseltine. Repetitive structure in the long terminal repeat element of a type II human T-cell leukemia virus. Proc Natl Acad Sci USA 1984; 81:4617-4621.
47. Sodroski J, R Patarca, D Perkins, D Briggs, T Lee, M Essex, J Colligan, F Wong-Staal, RC Gallo, WA Haseltine. Sequence of the envelope glycoprotein gene of type II human T-lymphotropic virus. Science 1984; 225:421-423.
48. Patarca R, C Heath, GJ Goldenberg, CA Rosen, JG Sodroski, WA Haseltine, UM Hansen. In vitro transcription directed by the HIV LTR AIDS. Res Human Retrovirus 1987; 3:41-56.
49. Ratner L, WA Haseltine, R Patarca, K Livak, B Starcich, SF Josephs, ER Doran, JA Rafalski, EA Whitehorn, K Baumeister, L Ivanoff, SR Petterway, ML Pearson, JA Lautenberger, TS Papas, J Ghrayeb, NT Chang, RC Gallo, F Wong-Staal. Complete nucleotide sequence of the AIDS virus HTLV-III. Nature 1985; 313:277-284.
50. Sodroski J, R Patarca, C Rosen, F Wong-Staal, WA Haseltine. Location of the trans-activating region on the genome of human T-cell lymphotropic virus type III. Science 1985; 229:74-77.
51. De Clercq E. Antiviral therapy for human immunodeficiency virus infections. Clin Microbiol Rev 1995; 8:200-239.
52. De Clercq E. In search of a selective antiviral chemotherapy. Clin Microbiol Rev 1997; 10: 674-693.
53. Elfassi E, R Patarca, WA Haseltine. Similarities among the pre-S regions of hepatitis B viruses. Analogy with retroviral transmembrane proteins. J Theor Biol 1986; 121:371-374.
54. Haseltine WA, R Patarca. AIDS virus and scrapie agent share protein. Nature 1986; 323: 115-116.
55. Hirsch MS, JC Kaplan. Treatment of human immunodeficiency virus infections. Antimicrob Agents Chemother 1987; 31:839-843.
56. Johnson MI, DF Hoth. Present status and future prospects for HIV therapies. Science 1993; 260: 1286-1293.
57. Mitsuya H, S Broder. Strategies for antiviral therapy in AIDS. Nature 1987; 325:773-778.
58. Mitsuya H, R Yarchoan, S Broder. Molecular targets for AIDS therapy. Science 1990; 249:1533-1544.
59. Patarca R, WA Haseltine. Sequence similarity among retroviruses. Nature 1984; 309:728.
60. Patarca R, WA Haseltine. Similarities among retrovirus proteins. Nature 1984; 312:496.
61. Patarca R, WA Haseltine. A major retroviral core protein related to EPA and TIMP. Nature 1985; 318:390.
62. Patarca R, WA Haseltine. Variation among the human T-lymphotropic virus type III (HTLV-III/LAV) strains. J Theor Biol 1986; 125:213-217.
63. Patarca R, WA Haseltine. Letter to the Editor. AIDS. Res Human Retrovirus 1987; 3:1-2.
64. Patarca R, B Dorta, JL Ramirez. Creation of a data base for sequences of ribosomal nucleic acids and detection of conserved restriction endonucleases sites through computerized processing. Nucleic Acids Res 1982; 10(1):175-182.
65. Patarca R, WA Haseltine, T Webster, TF Smith. Of how great significance. Nature 1987; 326:749.
66. Webster T, R Patarca, R Lathrop, TF Smith. Potential structural motifs for reverse transcriptases. Mol Biol Evol 1989; 6:317-320.
67. Yarchoan R, JM Pluda, CF Perno, H Mitsuya, S Broder. Anti-retroviral therapy of human immunodeficiency virus infection. Current strategies and challenges for the future. Blood 1991; 78(4): 859-884.
68. Hopp T, K Woods. Prediction of protein antigenic determinants from amino acid sequences. Proc Natl Acad Sci USA 1981; 78:3824.
69. Von Heijne G. A new method for predicting signal sequence cleavage sites. Nucleic Acids Res 1986; 14:4683.
70. Esparza J. The role of United Nations HIV/AIDS Program (UNAIDS) in the prevention of the viral transmission. Medicina 1998; 58:69-70.
71. McCune JM, R Namikawa, C-C Shih, L Robin, H Kaneshima. Suppression of HIV infection in AZT-treated SCID-hu mice. Science 1990; 247(4942): 564-566.
72. Mosier DE, RJ Gulizia, SM Baird, DB Wilson, DH Spector, SA Spector. Human immunodeficiency virus infection of human PBL-SCID mice. Science 1991; 251(4995):791-794.
73. Guy B, M Geist, K Dott, D Spehner, MP Kieny, JP Lecocq. A specific inhibitor of cysteine proteases impairs a Vif-dependent modification of human immunodeficiency virus type 1 Env protein. J Virol 1991; 65(3):1325-1331.
74. Schultz S. AIDS. No more silver bullet. US N World Rep 1998; 125(2):20-21.
75. Lerma JG, V Soriano, A Mas, ME Quinones-Mateu, EJ Arts, EJW Heneine. Quantitation of human immunodeficiency virus type 1 group O load in plasma by measuring reverse transcriptase activity. J Clin Microbiol 2000; 38(1):402-405.
76. Baum EZ, GA Bebernitz, Y Gluzman. Beta-galactosidase containing a human immunodeficiency virus protease cleavage site is cleaved and inactivated by human immunodeficiency virus protease. Proc Natl Acad Sci USA 1990; 87(24):10023-10027.
77. Gulnik S, JW Erickson, D Xie. HIV protease. Enzyme function and drug resistance. Vitam Horm 2000; 58:213-256.
78. Kaplan AH, M Manchester, T Smith, YL Yang, R Swanstrom. Conditional human immunodeficiency virus type 1 protease mutants show no role for the viral protease early in virus replication. J Virol 1996; 70(9):5840-5844.
79. Sommerfelt MA, SR Petteway Jr, GB Dreyer, E Hunter. Effect of retroviral proteinase inhibitors on Mason-Pfizer monkey virus maturation and transmembrane glycoprotein cleavage. J Virol 1992; 66(7):4220-4227.
80. Swanstrom R. Characterization of HIV-1 protease mutants. Random directed selected. Curr Opin Biotechnol 1994; 5(4):409-413.
81. Todd S, C Anderson, DJ Jolly, CS Craik. HIV protease as a target for retrovirus vector-mediated gene therapy. Biochim Biophys Acta 2000; 1477(1-2):168-188.
82. Todd S, MC Laboissiere, CS Craik. Yeast two-hybrid assay for examining human immunodeficiency virus protease heterodimer formation with dominant-negative inhibitors and multidrug-resistant variants. Anal Biochem 2000; 277(2):247-253.
83. Wondrak EM, JM Louis, PT Mora, S Oroszlan. Purification of HIV-1 wild-type protease and characterization of proteolytically inactive HIV-1 protease mutants by pepstatin A affinity chromatography. FEBS Lett 1991; 280(2):347-350.
84. Erickson JW, SW Fesik. Macromolecular X-crystallography and NM as tools for structure-based drug design. Annu Rev Med Chem 1992; 27:271-289.
85. Erickson J, DJ Neidhart, J Van Dri, DJ Kempf, XC Wang, DW Norbeck, JJ Plattner, JW Rittenhouse, M Turon, N Wideburg, et al. Design activity and 28 A crystal structure of C2 symmetric inhibitor complexed to HIV-1 protease. Science 1990; 249(4968):527-533.
86. Robins RK. Synthetic antiviral agents. Chem Eng News 1986; 27:28-40.
87. Tummino PJ, JVNV Prasad, D Ferguson, C Nouhan, N Graham, JM Dormagala, E Ellsworth, C Gajda, SE Hagen, EA Lunney, S Parak, BD Tait, A Pavlovsky, JW Erickson, S Gracheck, TJ McQuade, DJ Hupe. Discovery and optimization of nonpeptide HIV-1 protease inhibitors. Bioorg Med Chem Lett 1996; 4(9):1401-1410.
88. Wlodawer A, JW Erickson. Structure-based inhibitors of HIV-1 protease. Annu Rev Biochem 1993; 62:543-585.
89. Martinez MA, M Cabana, M Parera, A Gutierrez, JA Este, B Clotet. A bacteriophage lambda-based genetic screen for characterization of the activity and phenotype of the human immunodeficiency virus type 1 protease. Antimicrob Agents Chemother 2000; 44(5):1132-1139.
90. Heldsinger AA, T Antonucci. An HIV-1 protease screening assay using a non-infectious proviral clone. J Virol Methods 1994; 49(3):247-255.
91. Arrigo SJ, JK Haines, KM Huffman. Intrinsic activity of human immunodeficiency virus type 1 protease heterologous fusion proteins in mammalian cells. DNA Cell Biol 1995; 14(1):15-23.
92. Kiso Y. Approval of HIV protease inhibitors as the AIDS therapeutics of next generation. Nippon Rinsho 1997; 55(5):1287-1295.
93. Yamazaki T, LK Nicholson, DA Torchia, SJ Stahl, JD Kaufman, PT Wingfield, PJ Domaille, S Campbell-Burk. Secondary structure and signal assignments of human-immunodeficiency-virus-1 protease complexed to a novel structure-based inhibitor. Eur J Biochem 1994; 219(1-2):707-712.
94. Reddy NM, VN Viswanadhan, JN Weinstein. Relative differences in the binding free energies of human immunodeficiency virus 1 protease inhibitors. A thermodynamic cycle-perturbation approach. Proc Natl Acad Sci USA 1991; 88(22): 10287-10291.
95. Reddy MR, MD Varney, V Kalish, VN Viswanadhan, K Appelt. Calculation of relative differences in the binding free energies of HIV1 protease inhibitors: A thermodynamic cycle perturbation approach. J Med Chem 1994; 37(8):1145-1152.
96. Deeks SG. Failure of HIV-1 protease inhibitors to fully suppress viral replication Implications for salvage therapy. Adv Exp Med Biol 1999; 458: 175-182.
97. Rodgers JD, PY Lam, BL Johnson, H Wang, R Li, Y Ru, SS Ko, SP Seitz, GL Trainor, PS Anderson, RM Klabe, LT Bacheler, B Cordova, S Garber, C Reid, MR Wright, CH Chang, S Erickson-Viitanen. Design and selection of DMP 850 and DMP 851. The next generation of cyclic urea HIV protease inhibitors [published erratum appears in Chem Biol 1998; 5(11):R312]. Chem Biol 1998; 5(10):597-608.
98. Rodgers JD, PY Lam, BL Johnson, H Wang, R Li, Y Ru, SS Ko, SP Seitz, GL Trainor, PS Anderson, RM Klabe, LT Bacheler, B Cordova, S Garber, C Reid, MR Wright, CH Chang, S Erickson-Viitanen. Design and selection of DMP 850 and DMP 851. The next generation of cyclic urea HIV protease inhibitors [published erratum appears in Chem Biol 1998; 5(11):R312]. Chem Biol 1998; 5(10):597-608.
99. Kaplan AH, SF Michael, RS Wehbie, MF Knigge, DA Paul, L Everitt, DJ Kempf, DW Norbeck, JW Erickson, R Swanstrom. Selection of multiple human immunodeficiency virus type 1 variants that encode viral proteases with decreased sensitivity to an inhibitor of the viral protease. Proc Natl Acad Sci USA 1994; 91(12):5597-5601.
100. Ridky T J Leis. Development of drug resistance to HIV-1 protease inhibitors. J Biol Chem 1995; 270(50):29621-29623.
101. Mammano F, V Trouplin, V Zennou, F Clavel. Retracing the evolutionary pathways of human immunodeficiency virus type 1 resistance to protease inhibitors: Virus fitness in the absence and in the presence of drug. J Virol 2000; 74(18): 8524-8531.
102. Roberts NA, JC Craig, J Sheldon. Resistance and cross-resistance with saquinavir and other HIV protease inhibitors: Theory and practice. [Editorial]. AIDS 1998; 12(5):453-460.
103. Winters MA, JM Schapiro, J Lawrence, TC Merigan. Human immunodeficiency virus type 1 protease genotypes and in vitro protease inhibitor susceptibilities of isolates from individuals who were switched to other protease inhibitors after long-term saquinavir treatment. J Virol 1998; 72(6): 5303-5306.
104. Condra JH, WA Schleif, OM Blahy, LJ Gabryelski, DJ Graham, JC Quintero, A Rhodes, HL Robbins, E Roth, M Shivaprakash. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. [Comments]. Nature 1995; 374(6522): 569-571.
105. Deeks SG, FM Hecht, M Swanson, T Elbeik, R Loftus, PT Cohen, RM Grant. HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: Response to both initial and salvage therapy. AIDS 1999; 13: F35-F43.
106. Lallemand F, N Adda, V Schneider, C Jacomet, Y Salhi, W Rozenbaum. Prospective follow-up of 67 indinavir-experienced human immunodeficiency virus-infected and AIDS patients treated with the ritonavir/saquinavir combination. Clin Infect Dis 1999; 28(5):1184-1185.
107. Boucher CA, M Reedijk. Viral resistance: A major challenge in managing HIV disease. J Biol Regul Homeost Agents 1995; 9(3):91-94.
108. Cohen J. The daunting challenge of keeping HIV suppressed. [News]. Science 1997; 277(5322): 32-33.
109. Domingo E, L Menendez-Arias, ME Quinones-Mateu, A Holguin, M Gutierrez-Rivas, MA Martinez, J Quer, IS Novella, JJ Holland. Viral quasispecies and the problem of vaccine-escape and drug-resistant mutants. Prog Drug Res 1997; 48:99-128.
110. Erickson JW. The not-so-great escape. [Published erratum appears in Nature Struct Biol 1996; 3(1): 103]. Nature Struct Biol 1995; 2(7):523-529.
111. Erickson JW. The not-so-great escape. [Published erratum appears in Nature Struct Biol 1996; 3(1): 103]. Nature Struct Biol 1995; 2(7):523-529.
112. Jackson RC. A pharmacokinetic-pharmacodynamic model of chemotherapy of human immunodeficiency virus infection that relates development of drug resistance to treatment intensity. J Pharmacokinet Biopharm 1997; 25(6):713-730.
113. Lu W, W Zhang, SS Molloy, G Thomas, K Ryan, Y Chiang, S Anderson, M Laskowski Jr. Arg15-Lys17-Arg18 turkey ovomucoid third domain inhibits human furin. J Biol Chem 1993; 268(20). 14583-14585.
114. O'Brien WA. Resistance against reverse transcriptase inhibitors. Clin Infect Dis 2000; 30 Suppl 2: S185-S192.
115. Richman DD. Human immunodeficiency virus Protease uninhibited. [News, Comment]. Nature 1995; 374(6522):494.
116. Rosin CD, RK Belew, WL Walker, GM Morris, AJ Olson, DS Goodsell. Coevolution and subsite decomposition for the design of resistance-evading HIV-1 protease inhibitors. J Mol Biol 1999; 287(1): 77-92.
117. Rosin CD, RK Belew, GM Morris, AJ Olson, DS Goodsell. Coevolutionary analysis of resistance-evading peptidomimetic inhibitors of HIV-1 protease. Proc Natl Acad Sci USA 1999; 96(4): 1369-1374.
118. Jacobson MJ et al. Single-dose safety pharmacology and antiviral activity of the human immunodeficiency virus (HIV) type I entry inhibitor PRO 542 in HIV-infected adults. J Infect Dis 2000; 182: 321-329.
119. Kilby JM et al. Potent suppression of HIV-1 replication in humans by T-20 a peptide inhibitor of gp41-mediated virus entry. Nature Med 1998; 4: 1302-1307.
120. Nagashima KA et al. Human immunodeficiency virus type I entry inhibitors PRO 542 and T-20 are potentially synergistic in blocking virus-cell and cell-cell fusion. J Infect Dis 2001; 183: 1121-1125.
121. Schubert U, LC Anton, I Bacik, JH Cox, S Bour, JR Bennink, M Orlowski, K Strebel, JW Yewdell. CD4 glycoprotein degradation induced by human immunodeficiency virus type 1 Vpu protein requires the function of proteasomes and the ubiquitin-conjugating pathway. J Virol 1998; 72(3):2280-2288.
122. Wild CT et al. Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are portent inhibitors of virus infection. Proc Natl Acad Sci 1994; 91: 9770-9774.
123. Perelson AS, AU Neumann, M Markowitz, JM Leonard, DD Ho. HIV-1 dynamics in vivo: Virion clearance rate infected cell life-span and viral generation time. Science 1996; 271:1582-1586.
124. Wei X, SK Ghosh, ME Taylor, VA Johnson, EA Emini, P Deutsch, JD Lifson, S Bonhoeffer, MA Nowak, BH Hahn, et al. Viral dynamics in human immunodeficiency virus type 1 infection. [Comments]. Nature 1995; 373(6510):117-122.
125. Tucker SP, TR Stiebel Jr, KE Potts, ML Smidt, ML Bryant. Estimate of the frequency of human immunodeficiency virus type 1 protease inhibitor resistance within unselected virus populations in vitro. Antimicrob Agents Chemother 1998; 42(2): 478-480.
126. Yamaguchi K, RA Byrn. Clinical isolates of HIV-1 contain few pre-existing proteinase inhibitor resistance-conferring mutations. Biochim Biophys Acta 1995; 1253(2):136-140.
127. Mansky LM, Temin HM. Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase. J Virol 1995; 69:5087-5094.
128. Bratt G, E Sandstrom, J Albert, M Samson, B Wahren. The influence of MT-2 tropism on the prognostic implications of the delta32 deletion in the CCR-5 gene. AIDS 1997; 11(12):1415-1419.
129. Valdez H, SF Purvis, MM Lederman, M Fillingame, PA Zimmerman. Association of the CCR5delta32 mutation with improved response to antiretroviral therapy. [Letter]. JAMA 1999; 282(8):734.
130. Pereira FB, FM Goni, JL Nieva. Membrane fusion induced by the HIV type 1 fusion peptide: Modulation by factors affecting glycoprotein 41 activity and potential anti-HIV compounds AIDS. Res Human Retrovirus 1997; 13(14):1203-1211.
131. Moutouh L, J Corbeil, DD Richman. Recombination leads to the rapid emergence of HIV-1 dually resistant mutants under selective drug pressure. Proc Natl Acad Sci USA 1996; 93(12):6106-6011.
132. Yusa K, MF Kavlick, P Kosalaraksa, H Mitsuya. HIV-1 acquires resistance to two classes of antiviral drugs through homologous recombination. Antiviral Res 1997; 36(3):179-189.
133. Monno L, A Appice, R Cavaliere, T Scarabaggio, G Angarano. Highly active antiretroviral therapy failure and protease and reverse transcriptase human immunodeficiency virus type 1 gene mutations. [Letter, Comment]. J Infect Dis 1999; 180(2): 568-571.
134. Blower SM et al. Predicting the unpredictable: Transmission of drug-resistant HIV. Nature Med 2001; 7:1016-1020.
135. Hecht FM, RM Grant, CJ Petropoulos, B Dillon, MA Chesney, H Tian, NS Hellmann, NI Bandrapalli, L Digilio, B Branson, JO Kahn. Sexual transmission of an HIV-1 variant resistant to multiple reverse-transcriptase and protease inhibitors. N Engl J Med 1998; 339(5):307-311.
136. Salomon H, MA Wainberg, B Brenner, Y Quan, D Rouleau, P Cote, R LeBlanc, E Lefebvre, B Spira, C Tsoukas, RP Sekaly, B Conway, D Mayers, JP Routy. Prevalence of HIV-1 resistant to antiretroviral drugs in 81 individuals newly infected by sexual contact or injecting drug use. Investigators of the Quebec Primary Infection Study. AIDS 2000; 14(2):F17-F23.
137. Boden D, A Hurley, L Zhang, Y Cao, Y Guo, E Jones, J Tsay, J Ip, C Farthing, K Limoli, N Parkin, M Markowitz. HIV-1 drug resistance in newly infected individuals. [Comments]. JAMA 1999; 282(12):1135-1141.
138. Tamalet C, C Pasquier, N Yahi, P Colson, I Poizot-Martin, G Lepeu, H Gallais, P Massip, J Puel, J Izopet. Prevalence of drug resistant mutants and virological response to combination therapy in patients with primary HIV-1 infection. J Med Virol 2000; 61(2):181-186.
139. Little SJ, ES Daar, RT D'Aquila, PH Keiser, E Connick, JM Whitcomb, NS Hellmann, CJ Petropoulos, L Sutton, JA Pitt, ES Rosenberg, RA Koup, BD Walker, DD Richman. Reduced antiretroviral drug susceptibility among patients with primary HIV infection. [Comments]. JAMA 1999; 282(12):1142-1149.
140. Little S, E Darra, P Keiser. The spectrum and frequency of reduced antiretroviral drug susceptibility with primary infection in the united States. J Antiviral Ther 1999; 4(Suppl 1):86.
141. Dietrich U, I Raudonat, E Wolf, H Jager, R Husak, CE Orfanos, M Knickmann, H Knechten, H von Briesen, H Ruppach, A Immelmann. Indication for increasing prevalence of resistance mutations for protease inhibitors in therapy-naive HIV-1-positive German patients. [Letter]. AIDS 1999; 13(16):2304-2305.
142. Balotta C, M Violin, L Monno, P Bagnarelli, C Riva, G Facchi, A Berlusconi, M Lippi, S Rusconi, M Clementi, M Galli, G Angarano, M Moroni. Prevalence of multiple dideoxynucleoside analogue resistance (MddNR) in a multicenter cohort of HIV-1-infected Italian patients with virologic failure. J Acquir Immune Defic Synd 2000; 24(3): 232-240.
143. Balotta C, A Berlusconi, A Pan, M Violin, C Riva, MC Colombo, A Gori, L Papagno, S Corvasce, R Mazzucchelli, G Facchi, R Velleca, G Saporetti, M Galli, S Rusconi, M Moroni. Prevalence of transmitted nucleoside analogue-resistant HIV-1 strains and pre-existing mutations in pol reverse transcriptase and protease region: Outcome after treatment in recently infected individuals. Antiviral Ther 2000; 5(1):7-14.
144. Balotta C, A Berlusconi, A Pan, M Violin, C Riva, A Gori, S Corvasce, R Mazzucchelli, G Facchi, R Velleca, D Senese, L Deho, M Galli, S Rusconi, M Moroni. Prevalence of HIV-1 resistant strains in recent seroconverters. J Biol Regul Homeost Agents 2000; 14(1):51-57.
145. Birk M, A Sonnerborg. Variations in HIV-1 pol gene associated with reduced sensitivity to antiretroviral drugs in treatment-naive patients. AIDS 1998; 12(18):2369-2675.
146. Puig T, M Perez-Olmeda, A Rubio, L Ruiz, C Briones, JM Franco, M Gomez-Cano, L Stuyver, L Zamora, C Alvarez, M Leal, B Clotet, V Soriano. Prevalence of genotypic resistance to nucleoside analogues and protease inhibitors in Spain. The ERASE-2 Study Group. AIDS 2000; 14(6): 727-732.
147. th World AIDS Conference; June 28-July 3, 1998. Geneva. Abstract 32280.
148. Verhofstede C, FV Wanzeele, B Van Der Gucht, N De Cabooter, J Plum. Interruption of reverse transcriptase inhibitors or a switch from reverse transcriptase to protease inhibitors resulted in a fast reappearance of virus strains with a reverse transcriptase inhibitor-sensitive genotype. AIDS 1999; 13(18):2541-2546.
149. Rose RE, YF Gong, JA Greytok, CM Bechtold, BJ Terry, B S Robinson, M Alam, RJ Colonno, PF Lin. Human immunodeficiency virus type 1 viral background plays a major role in development of resistance to protease inhibitors. Proc Natl Acad Sci USA 1996; 93(4):1648-1653.
150. Casado JL, K Hertogs, L Ruiz, F Dronda, A Van Cauwenberge, A Arno, I Garcia-Arata, S Bloor, A Bonjoch, J Blazquez, B Clotet, B Larder. Non-nucleoside reverse transcriptase inhibitor resistance among patients failing a nevirapine plus protease inhibitor-containing regimen. AIDS 2000; 14(2): F1-F7.
151. Pilcher CD, MD Perkins, SA Fiscus, DM Johnston, R Dietze, UH Duque, AM Zago, F Assad-Antunes, JJ Eron. Genotypic resistance and the treatment of HIV-1 infection in Espirito Santo Brazil. J Infect Dis 1999; 179(5):1259-1263.
152. Izopet J, G Salama, C Pasquier, K Sandres, B Marchou, P Massip, J Puel. Decay of HIV-1 DNA in patients receiving suppressive antiretroviral therapy. J Acquir Immune Defic Syndr Human Retrovirol 1998; 19(5):478-483.
153. Wong JK, M Hezareh, HF Gunthard, DV Havlir, CC Ignacio, CA Spina, DD Richman. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. [Comments]. Science 1997; 278(5341):1291-1295.
154. Koch N, N Yahi, F Ariasi, J Fantini, C Tamalet. Comparison of human immunodeficiency virus type 1 (HIV-1) protease mutations in HIV-1 genomes detected in plasma and in peripheral blood mononuclear cells from patients receiving combination drug therapy. J Clin Microbiol 1999; 37(5):1595-1597.
155. Gunthard HF, JK Wong, CC Ignacio, JC Guatelli, NL Riggs, DV Havlir, DD Richman. Human immunodeficiency virus replication and genotypic resistance in blood and lymph nodes after a year of potent antiretroviral therapy. J Virol 1998; 72(3): 2422-2428.
156. Schapiro JM, MA Winters, M Vierra, S Crawford, TC Merigan. Lymph node human immunodeficiency virus RNA levels and resistance mutations in patients receiving high-dose saquinavir. J Infect Dis 1998; 177(2):477-480.
157. Venturi G, M Catucci, L Romano, P Corsi, F Leoncini, PE Valensin, M Zazzi. Antiretroviral resistance mutations in human immunodeficiency virus type 1 reverse transcriptase and protease from paired cerebrospinal fluid and plasma samples. J Infect Dis 2000; 181(2):740-745.
158. Eron JJ, PL Vernazza, DM Johnston. Resistance of HIV-1 to antiretroviral agents in blood and seminal plasma: Implications for transmission. AIDS 1998; 12(15):F181-F189.
159. Descamps D, P Flandre, V Calvez, G Peytavin, V. Meiffredy, G Collin, C Delaugerre, S Robert-Delmas, B Bazin, JP Aboulker, G Pialoux, F Raffi, F Brun-Vezinet. Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. Trilege (Agence Nationale de Recherches sur le SIDA 072) Study Team). [Comments]. JAMA 2000; 283(2): 205-211.
160. Mouroux M, A Yvon-Groussin, G Peytavin, C Delaugerre, M Legrand, P Bossi, B Do, A Trylesinski, B Diquet, E Dohin, JF Delfraissy, C Katlama, V Calvez. Early virological failure in naive human immunodeficiency virus patients receiving saquinavir (soft gel capsule)-stavudine-zalcitabine (MIKADO trial) is not associated with mutations conferring viral resistance. J Clin Microbiol 2000; 38(7): 2726-2730.
161. Nieuwkerk PT, MAG Sprangers, DM Burger, RMW Hoetelmans, PWH Hugen, SA Danner, ME van der Ende, MME Schneider, G Schrey, PL Meenhorst, HG Sprenger, RH Kauffmann, M Jambroes, MA Chesney, F de Wolf, JMA Lange for the Athena Project. Limited patient adherence to highly active antiretroviral therapy for HIV-1 infection in an observational cohort study. Arch Intern Med 2001; 161(16): 1962-1968.
162. Attaran A, L Gillespie-White. Do patents for antiretroviral drugs constrain access to AIDS treatment in Africa? JAMA 2001; 286(15):1886-1892.
163. Pecoul B, P Chirac, P Trouiller J Pinel. Access to essential drugs in poor countries: A lost battle? JAMA 1999; 281:361-367.
164. Anderson B, J Gallatin, R Toledo, N Hazam. An approach to the resolution of Mexican-American resistance to diagnostic and remedial pediatric health care. In: Chrisman NJ, TW Matretski, Editors. Clinically Applied Anthropology. The Netherlands: Dordrecht, 1982.
165. Elliott WJ. Compliance strategies. Curr Opin Nephrol Hypertens 1994; 3:271-278.
166. Gaines AD. Knowledge and practice: Anthropological ideas and psychiatric practice. In: Chrisman NJ, TW Matretski, Editors. Clinically Applied Anthropology. The Netherlands: Dordrecht, 1982.
167. Good BJ, M-JD Good. The meaning of symptoms: A cultural hermeneutic model for clinical practice. In: Eisenberg L, A Kleinman, Editors. The Relevance of Social Science for Medicine. The Netherlands: Dordrecht, 1981.
168. Ito KL. Health culture and the clinical encounter: Vietnamese refugees' responses to preventive drug treatment of inactive tuberculosis. Med Anthropol Q 1999; 13(3):338-364.
169. Kleinman A. Patients and Healers in the Context of Culture. Berkeley: University of California Press, 1980.
170. Pfifferling J-H. A cultural prescription for medicocentrism. In: Eisenberg L, A Kleinman, Editors. The Relevance of Social Science for Medicine. The Netherlands: Dordrecht, 1981.
171. Rideout M, R Menzies. Factors affecting compliance with preventive treatment for tuberculosis at Mitassini Lake Quebec Canada. Clin Invest Med 1994; 17(1):31-36.
172. Rudd P. Clinicians and patients with hypertension: Unsettled issues about compliance. Am Heart J 1995; 130:572-579.
173. Sackett DL, RB Haynes, GH Guyatt, P Tugwell. Clinical Epidemiology: A Basic Science for Clinical Medicine, Boston: Little Brown (1991).
174. Stoeckle JD, A Barsky. Attributions: Uses of social knowledge in the "doctoring" of primary care. In: Eisenberg L, A Kleinman, Editors. The Relevance of Social Science for Medicine. The Netherlands: Dordrecht, 1981.
175. Rubel AJ LC Garro. Cultural and social factors in the successful control of tuberculosis. Public Health Reports 1992; 107(6):626-636.
176. Shaffer NR, PA Chauchoowong, C Mock, et al. Short-course zidovudine for perinatal transmission of HIV-1 transmission in Bangkok Thailand: a randomized controlled trial. Lancet 1999; 353: 773-780.
177. Grosskurth H, F Mosha, J Todd, E Mwijarubi, A Klukke, K Senkuro, J Changalucha, A Nicoll, G Kajina. Impact of improved treatment of sexually transmitted diseases on HIV infection in rural Tanzania: randomized controlled trial. Lancet 1995; 346:530-536.
178. Pape J, S Jean, J Ho, A Hafner, WD Johnson Jr. Effect of isoniazid prophylaxis on incidence of active tuberculosis and progress of HIV infection. Lancet 1993; 342:268-272.
179. Wiktor SZ, M Sassan-Morokoro, A Grant, L Abouya, JM Karon, C Maurice, G Djomand, A Ackah, K Domova, A Kadio, A Yapi, P Combe, P Tosson, TH Roels, EM Lackritz, D Coulibaly, KM Decock, IM Coulibaly, AE Greenberg. Efficacy of trimethoprim-sulphamethoxazole prophylaxis to decrease morbidity and mortality in HIV-1 infected persons with tuberculosis in Abijanm Cote D'Ivoire: a randomized controlled trial. Lancet 1999; 353:1469-1475.
180. Anderson KH, JM Mitchell. Differential access on the receipt of antiretroviral drugs for the treatment of AIDS and its implications for survival. Arch Intern Med 2000; 160:3114-3120.
181. Hader SL, DK Smith, JS Moore, SD Holmberg. HIV infection in women in the United States Status at the millennium. JAMA 2001; 285(9): 1186-1192.
182. Isada CM. New developments in long-term treatment of HIV: the honeymoon is over. Cleveland Clin J Med 2001; 68(9):804-807.
183. Powderly WG, P Tebas. Nelfinavir, a new protease inhibitor: early clinical results. AIDS 1999; 13 (Suppl 1):S41-S48.
184. Molla A, S Vasavanonda, G Kumar, HL Sham, M Johnson, B Grabowski, JF Denissen, W Kohlbrenner, JJ Plattner, JM Leonard, DW Norbeck, DJ Kempf. Human serum attenuates the activity of protease inhibitors toward wild-type and mutant human immunodeficiency virus. Virology 1998; 250(2):255-262.
185. Molla A, GR Granneman, E Sun, DJ Kempf. Recent developments in HIV protease inhibitor therapy. Antiviral Res 1998; 39(1):1-23.
186. Dalmau D, A Ochoa de Echaguen. Evaluation of resistance to anti-retroviral agents. Publication of clinical trials. Enferm Infecc Microbiol Clin 1999; 17 Suppl 2:81-85.
187. Hirsch MS, B Conway, RT D'Aquila, VA Johnson, F Brun-Vezinet, B Clotet, LM Demeter, SM Hammer, DM Jacobsen, DR Kuritzkes, C Loveday, JW Mellors, S Vella, DD Richman. Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society, USA Panel. JAMA 1998; 279(24): 1984-1991.
188. Doyon L, G Croteau, D Thibeault, F Poulin, L Pilote, D Lamarre. Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors. J Virol 1996; 70(6):3763-3769.
189. Zhang YM, H Imamichi, T Imamichi, HC Lane, J Falloon, MB Vasudevachari, NP Salzman. Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites. J Virol 1997; 71(9):6662-6670.
190. Doyon L, C Payant, L Brakier-Gingras, D Lamarre. Novel Gag-Pol frameshift site in human immunodeficiency virus type 1 variants resistant to protease inhibitors. J Virol 72(7):6146-6150 (1998).
191. Carrillo A, KD Stewart, HL Sham, DW Norbeck, WE Kohlbrenner, JM Leonard, DJ Kempf, A Molla. In vitro selection and characterization of human immunodeficiency virus type 1 variants with increased resistance to ABT-378 a novel protease inhibitor. J Virol 1998; 72(9):7532-7541.
192. Bally F, R Martinez, S Peters, P Sudre, A Telenti. Polymorphism of HIV type 1 gag p7/p1 and p1/p6 cleavage sites: clinical significance and implications for resistance to protease inhibitors AIDS. Res Human Retrovirus 2000; 16(13):1209-1213.
193. Mammano F, C Petit, F Clavel. Resistance-associated loss of viral fitness in human immunodeficiency virus type 1: phenotypic analysis of protease and gag coevolution in protease inhibitor-treated patients. J Virol 1998; 72(9):7632-7637.
194. Lee YM, CJ Tian, XF Yu. A bipartite membrane-binding signal in the human immunodeficiency virus type 1 matrix protein is required for the proteolytic processing of Gag precursors in a cell type-dependent manner. J Virol 1998; 72(11): 9061-9068.
195. Bukovsky A, H Gottlinger. Lack of integrase can markedly affect human immunodeficiency virus type 1 particle production in the presence of an active viral protease. J Virol 1996; 70(10): 6820-6825.
196. Baxter JD, DL Mayers, DN Wentworth, JD Neaton, ML Hoover, MA Winters, SB Mannheimer, MA Thompson, DI Abrams, BJ Brizz, JPA Ioannidis, TC Merigan, the CPCRA 046 Study Team for the Terry Beim Community Programs for Clinical Research on AIDS (CPCRA). A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. AIDS 2000; 14(9):F83-F93.
197. Lee S-Y, M Griswold, L Shaker-Irwín, A Scarsella, E Rogolsky, R Stryker. Reproducibility precision and turn-around-times of results generated by laboratory-developed "home-brew" genotypic HIV-1 drug resistance assays vary dramatically when compared to results generated by a kit-based genotyping assay. 7th Annual Clinical Virology Symposium Clearwater, Florida. April 2001.
198. Larder B, V De Vroey, P Dehertogh, S Kemp, S Bloor, K Hertogs. Predicting HIV-1 phenotypic resistance from genotype using a large phenotype-genotype relational database. J Antiviral Ther 1999; 4 (Suppl 1):41.
199. Virco. Virco's Virtual "Phenotype." June 8, 2000.
200. Aizawa S, H Gatanaga, S Ida, A Sakai, M Tanaka, Y Takahashi, Y Hirabayashi, S Oka. Clinical benefits of resistance assay for HIV-specific protease inhibitors: when to check and in whom? [Letter]. AIDS 1999; 13(10):1278-1279.
201. Deeks SG, DI Abrams. Genotypic-resistance assays and antiretroviral therapy. Lancet 1997; 349(9064): 1489-1490.
202. Durant J, P Clevenbergh, P Halfon, P Delgiudice, S Porsin, P Simonet, N Montagne, CA Boucher, JM Schapiro, P Dellamonica. Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial. [Published erratum appears in Lancet 1999; 354(9184):1128]. Lancet 1999; 353(9171):2195-2199.
203. Durant J, P Clevenbergh, P Halfon, P Delgiudice, S Porsin, P Simonet, N Montagne, CA Boucher, JM Schapiro, P Dellamonica. Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial. [Published erratum appears in Lancet 1999; 354(9184):1128]. Lancet 1999; 353(9171):2195-2199.
204. th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 17-20, Toronto, Ontario. Abstract L-10, 2000.
205. Cohen CJ, K Hessler, S Hunt, M Sension, C Farthing, M Conant, et al. Phenotyping resistance testing significantly improves response to therapy: final analysis of a randomized trial (VIRA 3001). Abstract]. Antiviral Ther 2000; 5 (Suppl. 3):67.
206. Meynard JL, M Vray, L Morand-Joubert, et al. Impact of treatment guided by phenotypic or genotypic resistance tests on the response to antiretroviral therapy: a randomized trial (NARVAL, ANRS 088). Antiviral Ther 2000; 5 (Suppl. 3):67.
207. th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 17-20, Toronto, Ontario. Oral presentation 698, 2000.
208. Cabana M, B Clotet, MA Martinez. Emergence and genetic evolution of HIV-1 variants with mutations conferring resistance to multiple reverse transcriptase and protease inhibitors. J Med Virol 1999; 59(4):480-490.
209. Piketty C, E Race, P Castiel, L Belec, G Peytavin, A Si-Mohamed, G Gonzalez-Canali, L Weiss, F Clavel, MD Kazatchkine. Efficacy of a five-drug combination including ritonavir, saquinavir and efavirenz in patients who failed on a conventional triple-drug regimen: phenotypic resistance to protease inhibitors predicts outcome of therapy. AIDS 1999; 13(11):F71-F77.
210. Rusconi S, S La Seta Catamancio, P Citterio, S Kurtagic, M Violin, C Balotta, M Moroni, M Galli, A D'Arminio-Monforte. Susceptibility to PNU-140690 (Tipranavir) of human immunodeficiency virus type 1 isolates derived from patients with multidrug resistance to other protease inhibitors. Antimicrob Agents Chemother 2000; 44(5): 1328-1332.
211. Belec L, C Piketty, A Si-Mohamed, C Goujon, MC Hallouin, S Cotigny, L Weiss, MD Kazatchkine. High levels of drug-resistant human immunodeficiency virus variants in patients exhibiting increasing CD4+ T cell counts despite virologic failure of protease inhibitor-containing antiretroviral combination therapy. J Infect Dis 2000; 181(5): 1808-1812.
212. Atkinson B, J Isaacson, M Knowles, E Mazabel, AK Patick. Correlation between human immunodeficiency virus genotypic resistance and virologic response in patients receiving nelfinavir monotherapy or nelfinavir with lamivudine and zidovudine. J Infect Dis 2000; 182(2):420-427.
213. Cohen CJ, K Hessler, S Hunt, M Sension, C Farthing, M Conant, et al. Phenotyping resistance testing significantly improves response to therapy: final analysis of a randomized trial (VIRA 3001). [Abstract]. Antiviral Ther 2000; 5 (Suppl. 3):67.
214. Nijhuis M., Schuurman R, de Jong D, Erickson J, Gustchina E, Albert J, Schipper P, Gulnik S, Boucher CA. Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy AIDS 1999; 13:2349-2359.
215. Berkhout B. HIV-1 evolution under pressure of protease inhibitors: climbing the stairs of viral fitness. J Biomed Sci 1999; 6298-305.
216. Mahalingam B, Louis JM, Reed CC, Adomat JM, Krouse J, Wang YF, Harrison RW, Weber IT. Structural and kinetic analysis of drug resistant mutants of HIV-1 protease. Eur J Biochem 1999; 263:238-245.
217. Dela Carriere LC, Paulous S, Clavel F, Mammano F. Effects of human immunodeficiency virus type 1 resistance to protease inhibitors on reverse transcriptase processing, activity, and drug sensitivity. J Virol 1999; 73:3455-3459.
218. Wang CT, Chou YC, Chiang CC. Assembly and processing of human immunodeficiency virus Gag mutants containing a partial replacement of the matrix domain by the viral protease domain. J Virol 2000; 74:3418-3422.
219. Kuroda MJ, el-Farrash MS, Choudhury S, Harada S. Impaired infectivity of HIV-1 after a single point mutation in the POL gene to escape the effect of a protease inhibitor in vitro. Virology 1995; 210: 212-216.
220. Dulioust A, Paulous S, Guillemot L, Delavalle AM, Boue F, Clavel F. Constrained evolution of human immunodeficiency virus type 1 protease during sequential therapy with two distinct protease inhibitors. J Virol 1999; 73:850-854.
221. Mammano F., Trouplin V, Zennou V, Clavel F. Retracing the evolutionary pathways of human immunodeficiency virus type 1 resistance to protease inhibitors: virus fitness in the absence and in the presence of drug. J Virol 2000; 74:8524-8531.
222. Croteau G, Doyon L, Thibeault D, McKercher G, Pilote L, Lamarre D. Impaired fitness of human immunodeficiency virus type 1 variants with high-level resistance to protease inhibitors. J Virol 1997; 71:1089-1096.
223. Borman AM, Paulous S, Clavel F. Resistance of human immunodeficiency virus type 1 to protease inhibitors: selection of resistance mutations in the presence and absence of the drug. J Gen Virol 1996; 77 (Pt 3):419-426.
224. Brown AJ, Korber BT, Condra JH. Associations between amino acids in the evolution of HIV type 1 protease sequences under indinavir therapy. AIDS Res Hum Retrovir 1999; 15:247-253.
225. Patick AK, Rose R, Greytok J, Bechtold CM, Hermsmeier MA, Chen PT, Barrish JC, Zahler R, Colonno RJ, Lin PF. Characterization of a human immunodeficiency virus type 1 variant with reduced sensitivity to an aminodiol protease inhibitor. J Virol 1995; 69:2148-2152.
226. Jacobsen H, Yasargil K, Winslow DL, Craig JC, Krohn A, Duncan IB Mous J. Characterization of human immunodeficiency virus type 1 mutants with decreased sensitivity to proteinase inhibitor Ro 31-8959. Virology 1995; 206:527-534.
227. Turriziani O, Antonelli G, Jacobsen H, Mous J, Riva E, Pistello M, Dianzani F. Identification of an amino acid substitution involved in the reduction of sensitivity of HIV-1 to an inhibitor of viral proteinase. Acta Virol 1994; 38:297-298.
228. Ives KJ, Jacobsen H, Galpin SA, Garaev MM, Dorrell L, Mous J, Bragman K, Weber JN. Emergence of resistant variants of HIV in vivo during monotherapy with the proteinase inhibitor saquinavir. J Antimicrob Chemother 1997; 39:771-779.
229. Boucher C. Rational approaches to resistance: using saquinavir. AIDS 1996; 10 (Suppl. 1):S15-S19.
230. Powderly WG, Tebas P. Nelfinavir, a new protease inhibitor: early clinical results. AIDS 1999; 13 (Suppl 1):S41-S48.
231. Jarvis B, Faulds D. Nelfinavir. A review of its therapeutic efficacy in HIV infection. Drugs 1998; 56: 147-167.
232. Markowitz M, Conant M, Hurley A, Schluger R, Duran M, Peterkin J, Chapman S, Patick A, Hendricks A, Yuen GJ, Hoskins W, Clendeninn N, Ho DD. A preliminary evaluation of nelfinavir mesylate, an inhibitor of human immunodeficiency virus (HIV)-1 protease, to treat HIV infection. J Infect Dis 1998; 177:1533-1540.
233. Lin Y, Lin X, Hong L, Foundling S, Heinrikson RL, Thaisrivongs S, Leelamanit W, Raterman D, Shah M, Dunn BM. Effect of point mutations on the kinetics and the inhibition of human immunodeficiencyvirus type 1 protease: relationship to drug resistance. Biochemistry 1995; 34:1143-1152.
234. Maschera B, Darby G, Palu G, Wright LL, Tisdale M, Myers R, Blair ED, Furfine ES. Human immunodeficiency virus. Mutations in the viral protease that confer resistance to saquinavir increase the dissociation rate constant of the protease-saquinavir complex. J Biol Chem 1996; 271:33231-33235.
235. Maschera B, Furfine E, Blair ED. Analysis of resistance to human immunodeficiency virus type 1 protease inhibitors by using matched bacterial expression and proviral infection vectors. J Virol 1995; 69:5431-5436.
236. Partaledis JA, Yamaguchi K, Tisdale M, Blair EE, Falcione C, Maschera B, Myers RE, Pazhanisamy S, Futer O, CuUinan AB. In vitro selection and characterization of human immunodeficiency virus type 1 (HIV-1) isolates with reduced sensitivity to hydroxyethylamino sulfonamide inhibitors of HIV-1 aspartyl protease. J Virol 1995; 69:5228-5235.
237. Tisdale M, Myers RE, Maschera B, Parry NR, Oliver NM, Blair ED. Cross-resistance analysis of human immunodeficiency virus type 1 variants individually selected for resistance to five different protease inhibitors. Antimicrob Agents Chemother 1995; 39:1704-1710.
238. Gulnik SV, Suvorov LI, Liu B, Yu B, Anderson B, Mitsuya H, Erickson JW. Kinetic characterization and cross-resistance patterns of HIV-1 protease mutants selected under drug pressure. Biochemistry 1995; 34:9282-9287.
239. Klabe RM, Bacheler LT, Ala PJ, Erickson-Viitanen S, Meek JL. Resistance to HIV protease inhibitors: a comparison of enzyme inhibition and antiviral potency. Biochemistry 1998; 37:8735-8742.
240. Wilson SI, Phylip LH, Mills JS, Gulnik SV, Erickson JW, Dunn BM, Kay J. Escape mutants of HIV-1 proteinase: enzymic efficiency and susceptibility to inhibition. Biochim Biophys Acta 1997; 1339: 113-125.
241. Vasudevachari MB, Zhang YM, Imamichi H, Imamichi T, Falloon J, Salzman NP. Emergence of protease inhibitor resistance mutations in human immunodeficiency virus type 1 isolates from patients and rapid screening procedure for their detection. Antimicrob Agents Chemother 1996; 40:2535-2541.
242. Schmit JC, Ruiz L, Clotet B, Raventos A, Tor J, Leonard J, Desmyter J, De Clercq E, Vandamme AM. Resistance-related mutations in the HIV-1 protease gene of patients treated for 1 year with the protease inhibitor ritonavir (ABT-538). AIDS 1996; 10:995-999.
243. Pazhanisamy S, Stuver CM, Cullinan AB, Margolin N, Rao BG, Livingston DJ. Kinetic characterization of human immunodeficiency virus type-1 protease-resistant variants. J Biol Chem 1996; 271:17979-17985.
244. Molla A, Komeyeva M, Gao Q, Vasavanonda S, Schipper PJ, Mo HM, Markowitz M, Chemyavskiy T, Niu P, Lyons N, Hsu A, Granneman GR, Ho DD, Boucher CA, Leonard JM, Norbeck DW, Kempf DJ. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nature J Med 1996; 2:760-766.
245. Jacobsen H, Hanggi M, Ott M, Duncan IB, Owen S, Andreoni M, Vella S, Mous J. In vivo resistance to a human immunodeficiency virus type 1 proteinase inhibitor: mutations, kinetics, and frequencies. J Infect Dis 1996; 173:1379-1387.
246. Jacobsen H, Haenggi M, Ott M, Duncan IB, Andreoni M, Vella S, Mous J. Reduced sensitivity to saquinavir: an update on genotyping from phase I/II trials. Antivir Res 1996; 29:95-97.
247. Markland W, Rao BG, Parsons JD, Black J, Zuchowski L, Tisdale M, Tung R. Structural and kinetic analyses of the protease from an amprenavir-resistant human immunodeficiencyvirus type 1 mutant rendered resistant to saquinavir and resensitized to amprenavir. J Virol 2000; 74:7636-7641.
248. Schock HB, Garsky VM, Kuo LC. Mutational anatomy of an HIV-1 protease variant conferring cross-resistance to protease inhibitors in clinical trials. Compensatory modulations of binding and activity. J Biol Chem 1996; 271:31957-31963.
249. Eastman PS, Mittler J, Kelso R, Gee C, Boyer E, Kolberg J, Urdea M, Leonard JM, Norbeck DW, Mo H, Markowitz M. Genotypic changes in human immunodeficiency virus type 1 associated with loss of suppression of plasma viral RNA levels in subjects treated with ritonavir (Norvir) monotherapy. J Virol 1998; 72:5154-5164.
250. Ziermann R, Limoli K, Das K, Arnold E, Petropoulos CJ, Parkin NT. A mutation in human immunodeficiency virus type 1 protease, N88S, that causes in vitro hypersensitivity to amprenavir. J Virol 2000; 74:4414-4419.
251. Smidt ML, Potts KE, Tucker SP, Blystone L, Stiebel TR Jr., Stallings WC, McDonald JJ, Pillay D, Richman DD, Bryant ML. A mutation in human immunodeficiency virus type 1 protease at position 88, located outside the active site, confers resistance to the hydroxyethylurea inhibitor SC-55389A. Antimicrob Agents Chemother 1997; 41: 515-522.
252. Gong YF, Robinson BS, Rose RE, Deminie C, Spicer TP, Stock D, Colonno RJ, Lin PF. In vitro resistance profile of the human immunodeficiency virus type 1: protease inhibitor BMS-232632. Antimicrob Agents Chemother 2000; 44:2319-2326.
253. Nillroth U, Vrang L, Markgren PO, Hulten J, Hallberg A, Danielson UH. Human immunodeficiency virus type 1 proteinase resistance to symmetric cyclic urea inhibitor analogs. Antimicrob Agents Chemother 1997; 41:2383-2388.
254. Pazhanisamy S, Partaledis JA, Rao BG, Livingston DJ. In vitro selection and characterization of VX-478 resistant HIV-1 variants. Adv Exper Med Biol 1998; 436:75-83.
255. Lin YC, Beck Z, Lee T, Le VD, Morris GM, Olson AJ, Wong CH, Elder JH. Alteration of substrate and inhibitor specificity of feline immunodeficiency virus protease. J Virol 2000; 74:4710-4720.
256. Powell DJ, Bur D, Wlodawer A, Gustchina A, Payne SL, Dunn BM, Kay J. Expression, characterisation and mutagenesis of the aspartic proteinase from equine infectious anaemia virus [Erratum: Eur. J. Biochem 1997; 246:258]. Eur J Biochem 1996; 241:664-674.
257. Powell DJ, Bur D, Wlodawer A, Gustchina A, Payne SL, Dunn BM, Kay J. Expression, characterisation and mutagenesis of the aspartic proteinase from equine infectious anaemia virus [Erratum: Eur. J. Biochem 1997; 246:258]. Eur J Biochem 1996; 241:664-674.
258. Martinez G, Sarria L, Campelo C, Merchan A, Cisterna R. [Evaluation of mutations that confer resistance to nudeoside analogs and protease inhibitors in HIV-1-infected patients. Study Group on Resistance to Antiretroviral Agents]. Rev Esp Quimioter 1999; 12:317-324.
259. Keulen W, Boucher C, Berkhout B. Nudeotide substitution patterns can predict the requirements for drug-resistance of HIV-1 proteins. Antivir Res 1996; 31:45-57.
260. Pauwels R, Andries K, Debyser Z, Kukla MJ, Schols D, Breslin HJ, Woestenborghs R, Desmyter J, Janssen MA, De Clercq E, Janssen PAJ. New tetrahydroimidazo[4,5,1-jk][1,4]-benzodiazepin-2(1H)-one and -thione derivatives are potent inhibitors of human immunodeficiency virus type 1 replication and are synergistic with 2′,3′-dideoxynudeoside analogs. Antimicrob Agents Chemother 1994; 38: 2863-2870.
261. Wainberg MA, Drosopoulos WC, Salomon H, Hsu M, Borkow G, Parniak M, Gu Z, Song Q, Manne J, Islam S, Castriota G, Prasad VR. Enhanced fidelity of 3TC-selected mutant HIV-1 reverse transcriptase [See comments]. Science 1996; 271: 1282-1285.
262. Catucci M, Venturi G, Romano L, Riccio ML, De Milito A, Valensin PE, Zazzi M. Development and significance of the HIV-1 reverse transcriptase M184V mutation during combination therapy with lamivudine, zidovudine, and protease inhibitors. J Acquir Immune Defic Syndr 1999; 21:203-208.
263. Keulen W, van Wijk A, Schuurman R, Berkhout B, Boucher CA. Increased polymerase fidelity of lamivudine-resistant HIV-1 variants does not limit their evolutionary potential. AIDS 1999; 13: 1343-1349.
264. Schmitt M, Harrer E, Goldwich A, Bauerle M, Graedner I, Kalden JR, Harrer T. Specific recognition of lamivudine-resistant HIV-1 by cytotoxic T lymphocytes. AIDS 2000; 14:653-658.
265. Wallqvist A, Smythers GW, Covell DG A cooperative folding unit in HIV-1 protease. Implications for protein stability and occurrence of drug-induced mutations. Protein Eng 1998; 11:999-1005.
266. Schaffer L, Verkhivker GM. Predicting structural effects in HIV-1 protease mutant complexes with flexible ligand docking and protein side-chain optimization. Proteins 1998; 33:295-310.
267. Sussman F, Villaverde MC, Davis A Solvation effects are responsible for the reduced inhibitor affinity of some HIV-1 PR mutants. Protein Sci 1997; 6:1024-1030.
268. Tang J, Hartsuck JA. A kinetic model for comparing proteolytic processing activity and inhibitor resistance potential of mutant HIV-1 proteases. FEBS Lett 1995; 367:112-116.
269. Shultz MD, Chmielewski J. Probing the role of interfacial residues in a dimerization inhibitor of HIV-1 protease. Bioorg Med Chem Lett 1999; 9: 2431-2436.
270. Rose RB, Craik CS, Stroud RM. Domain flexibility in retroviral proteases: structural implications for drug resistant mutations. Biochemistry 1998; 37: 2607-2621.
271. Collins JR, Burt SK, Erickson JW. Flap opening in HIV-1 protease simulated by "activated" molecular dynamics. Nature Struct Biol 1995; 2:334-338.
272. Baldwin ET, Bhat TN, Liu B, Pattabiraman N, Erickson JW. Structural basis of drug resistance for the V82A mutant of HIV-1 proteinase. Nature Struct Biol 1995; 2:244-249.
273. Markowitz M, Mo H, Kempf DJ, Norbeck DW, Bhat TN, Erickson JW, Ho DD. Selection and analysis of human immunodeficiency virus type 1 variants with increased resistance to ABT-538, a novel protease inhibitor. J Virol 1995; 9:701-706.
274. Chen Z, Li Y, Schock HB, Hall D, Chen E, Kuo LC. Three-dimensional structure of a mutant HIV-1 protease displaying cross-resistance to all protease inhibitors in clinical trials. J Biol Chem 1995; 270: 21433-21436.
275. Hong L, Zhang KJ, Foundling S, Hartsuck JA, Tang J. Structure of a G48H mutant of HIV-1 protease explains how glycine-48 replacements produce mutants resistant to inhibitor drugs. FEBS Lett 1997; 420:11-16.
276. Verkhivker GM. Empirical free energy calculations of human immunodeficiency virus type 1 protease crystallographic complexes. II. Knowledge-based ligand-protein interaction potentials applied to thermodynamic analysis of hydrophobic mutations. Pacific Symp Biocomput 1996; 638-652.
277. Hong L, Trehame A, Hartsuck JA, Foundling S, Tang J. Crystal structures of complexes of a peptidic inhibitor with wild-type and two mutant HIV-1 proteases. Biochemistry 1996; 35:10627-10633.
278. Hoog SS, Towler EM, Zhao B, Doyle ML, Debouck C, Abdel-Meguid SS. Human immunodeficiency virus protease ligand specificity conferred by residues outside of the active site cavity. Biochemistry 1996; 35:10279-10286.
279. Erickson JW, Burt SK. Structural mechanisms of HIV drug resistance. Ann Rev Pharmacol Toxicol 1996; 36:545-571.
280. Wang YX, Freedberg DI, Yamazaki T, Wingfield PT, Stahl DJ, Kaufman JD, Kiso Y, Torchia DA. Solution NMR evidence that the HIV-1 protease catalytic aspartyl groups have different ionization states in the complex formed with the asymmetric drug KNI-272 [Erratum: Biochemistry 1997; 36: 280]. Biochemistry 1997; 35:9945-9950.
281. Wang YX, Freedberg DI, Yamazaki T, Wingfield PT, Stahl DJ, Kaufman JD, Kiso Y, Torchia DA. Solution NMR evidence that the HIV-1 protease catalytic aspartyl groups have different ionization states in the complex formed with the asymmetric drug KNI-272 [Erratum: Biochemistry 1997; 36: 280]. Biochemistry 1997; 35:9945-9950.
282. Rosin CD, Belew RK, Walker WL, Morris GM, Olson AJ, Goodsell DS. Coevolution and subsite decomposition for the design of resistance-evading HIV-1 protease inhibitors. J Mol Biol 1999; 287: 77-92.
283. Rosin CD, Belew RK, Morris GM, Olson AJ, Goodsell DS. Coevolutionary analysis of resistance-evading peptidomimetic inhibitors of HIV-1 protease. Proc Nat Acad Sci USA 1999; 96:1369-1374.
284. Jadhav PK, Ala P, Woerner FJ, Chang CH, Garber SS, Anton ED, Bacheler LT. Cyclic urea amides: HIV-1 protease inhibitors with low nanomolar potency against both wild type and protease inhibitor resistant mutants of HIV. J Med Chem 1997; 40: 181-191.
285. Rodgers JD, Lam PY, Johnson BL, Wang H, Li R, Ru Y, Ko SS, Seitz SP, Trainor GL, Anderson PS, Klabe RM, Bacheler LT, Cordova B, Garber S, Reid C, Wright MR, Chang CH, Erickson-Viitanen S. Design and selection of DMP 850 and DMP 851: the next generation of cyclic urea HIV protease inhibitors [Erratum: Chem Biol 1996; 5:R312] Chem Biol 1998; 5:597-608.
286. Rodgers JD, Lam PY, Johnson BL, Wang H, Li R, Ru Y, Ko SS, Seitz SP, Trainor GL, Anderson PS, Klabe RM, Bacheler LT, Cordova B, Garber S, Reid C, Wright MR, Chang CH, Erickson-Viitanen S. Design and selection of DMP 850 and DMP 851: the next generation of cyclic urea HIV protease inhibitors [Erratum: Chem Biol 1996; 5:R312] Chem Biol 1998; 5:597-608.
287. De Lucca GV, Kim UT, Liang J, Cordova B, Klabe RM, Garber S, Bacheler LT, Lam GN, Wright MR, Logue KA, Erickson-Viitanen S, Ko SS, Trainor GL. Nonsymmetric P2/P2′ cyclic urea HIV protease inhibitors. Structure-activity relationship, bioavailability, and resistance profile of monoindazole-substituted P2 analogues. J Med Chem 1998; 41:2411-2423.
288. Prasad JV, Boyer FE, Domagala JM, Ellsworth EL, Gajda C, Hamilton HW, Hagen SE, Markoski LJ, Steinbaugh BA, Tait BD, Humblet C, Lunney EA, Pavlovsky A, Rubin JR, Ferguson D, Graham N, Holler T, Hupe D, Nouhan C, Tummino J, Urumov A, Zeikus E, Zeikus G, Gracheck SJ, Erickson JW. Nonpeptidic HIV protease inhibitors possessing excellent antiviral activities and therapeutic indices. PD 178390: a lead HIV protease inhibitor. Bioorg Med Chem 1999; 7:2775-2800.
289. Schramm HJ, de Rosny E, Reboud-Ravaux M, Buttner J, Dick A, Schramm W. Lipopeptides as dimerization inhibitors of HIV-1 protease. Biol Chem 1999; 380:593-596.
290. Todd S, Anderson C, Jolly DJ, C.S. Craik CS. HIV protease as a target for retrovirus vector-mediated gene therapy. Biochim Biophys Acta 2000; 1477: 168-188.
291. Todd S, Laboissiere MC, Craik CS. Yeast two-hybrid assay for examining human immunodeficiency virus protease heterodimer formation with dominant-negative inhibitors and multidrug-resistant variants. Anal Biochem 2000; 277:247-253.
292. El-Farrash MA, Kuroda MJ, Kitazaki T, Masuda T, Kato K, Hatanaka M, Harada S. Generation and characterization of a human immunodeficiency virus type 1 (HIV-1) mutant resistant to an HIV-1 protease inhibitor. J Virol 1994; 68:233-239.
293. McNeely TB, Shugars DC, Rosendahl M, Tucker C, Eisenberg SP, Wahl SM. Inhibition of human immunodeficiency virus type 1 infectivity by secretory leukocyte protease inhibitor occurs prior to viral reverse transcription. Blood 1997; 90:1141-1149.
294. Said B, Matsumoto DC, Hamade AK, Shank RC. Mutagenic activity and DNA adduct formation by 1, 2-epoxy-3-(p-nitrophenoxy)propane, an HIV-1 protease inhibitor and GST substrate. Biochem Biophys Res Comm 1999; 261:844-847.
295. Tanaka Y, Kameoka M, Ota K, Itaya A, Ikuta K, Yoshihara K. Establishment of persistent infection with HIV-1 abrogates the caspase-3-dependent apoptotic signaling pathway in U937 cells. Exper Cell Res 1999; 247:514-524.
296. Wu X, Liu H, Xiao H, Conway JA, Kappes JC. Inhibition of human and simian immunodeficiency virus protease function by targeting Vpx-protease-mutant fusion protein into viral particles. J Virol 1996; 70:3378-3384.
297. O'Brien WA. Resistance against reverse transcriptase inhibitors. Clin Infect Dis 2000; 20 (Suppl 2): S185-S192.
298. Moyle GJ. Use of viral resistance patterns to antiretroviral drugs in optimising election of drug combinations and sequences. Drugs 1996; 52: 168-185.
299. Dalmau D, Ochoa de Echaguen A. [Evaluation of resistance to anti-retroviral agents. Publication of clinical trials]. Enfermed Infec Microbiol Clin 1999; 17 (Suppl 2):81-85.
300. Larder BA. Viral resistance and the selection of antiretroviral combinations. J Acquir Immune Defic Syndr Hum Retrovirol 1995; 10 (Suppl. 1): S28-S33.
301. Lawrence J, Schapiro J, Winters M, Montoya J, Zolopa A, Pesano R, Efron B, Winslow D, Merigan TC. Clinical resistance patterns and responses to two sequential protease inhibitor regimens in saquinavir and reverse transcriptase inhibitor-experienced persons. J Infect Dis 1999; 179:1356-1364.
302. Churchill DR, Pym AS, Galpin S, Foxall R, Stainsby C, Clarke JR, Kaye S, Bloor S, Larder BA, Wills B, Sun E, Babiker AG, Back DJ, Weber JN. The rabbit study: ritonavir and saquinavir in combination in saquinavir-experienced and previously untreated patients. AIDS Res Hum Retrovir 1999; 15:1181-1189.
303. +T-cell counts in HIV-infected patients [see comments]. Ann Intern Med 1996; 124:1039-1050.
304. Winters MA, Baxter JD, Mayers DL, Wentworth DN, Hoover ML, Neaton JD, Merigan TC. Frequency of antiretroviral drug resistance mutations in HIV-1 strains from patients failing triple drug regimens. The Terry Beirn Community Programs for Clinical Research on AIDS. Antivir Ther 2000; 5:57-63.
305. Descamps D, Flandre P, Calvez V, Peytavin G, Meiffredy V, Collin G, Delaugerre C, Robert-Delmas S, Bazin B,. Aboulker JP, Pialoux G, Raffi F, Brun-Vezinet F. Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. Trilege (Agence Nationale de Recherches surle SIDA 072) Study Team) JAMA 2000; 283:205-211.
306. Schapiro JM, Lawrence J, Speck R, Winters MA, Efron B, Coombs RW, Collier AC, Merigan TC. Resistance mutations to zidovudine and saquinavir in patients receiving zidovudine plus saquinavir or zidovudine and zalcitabine plus saquinavir in AIDS clinical trials group 229. J Infect Dis 1999; 179: 249-253.
307. Young B, Johnson S, Bahktiari M, Shugarts D, Young RK, Allen M, Ramey RR 2nd, Kuritzkes DR. Resistance mutations in protease and reverse transcriptase genes of human immunodeficiency virus type 1 isolates from patients with combination antiretroviral therapy failure [see comments]. J Infect Dis 1998; 178:1497-1501.
308. Race E, Gilbert SM, Sheldon JG, Rose JS, Moffatt AR, Sitbon G,
309. Deeks SG, Grant RM, Beatty FW, Horton C, Detmer J, Eastman S. Activity of a ritonavir plus saquinavir-containing regimen in patients with virologic evidence of indinavir or ritonavir failure. AIDS 1998; 12:F97-F102.
310. Batisse D, Karmochkine M, Si Mohamed A, Piketty C, Kazatchkine MD, Belec L. Persistence of HIV-1 variants harbouring the zidovudine resistance mutation at pol codon 215 in patients who respond to triple combination therapy [letter]. AIDS 1998; 12:824-825.
311. Winters MA, Schapiro JM, Lawrence J, Merigan TC. Human immunodeficiency virus type 1 protease genotypes and in vitro protease inhibitor susceptibilities of isolates from individuals who were switched to other protease inhibitors after long-term saquinavir treatment. J Virol 1998; 72: 5303-5306.
312. Race E, Dam E, Obry V, Paulous S, Clavel F. Analysis of HIV cross-resistance to protease inhibitors using a rapid single-cyde recombinant virus assay for patients failing on combination therapies. AIDS 1999; 13:2061-2068.
313. Falloon J, Piscitelli S, Vogel S, Sadler B, Mitsuya H, Kavlick MF, Yoshimura K, Rogers M, LaFon S, Manion DJ, Lane HC, Masur H. Combination therapy with amprenavir, abacavir, and efavirenz in human immunodeficiency virus (HIV)-infected patients failing a protease-inhibitor regimen: pharmacokinetic drug interactions and antiviral activity. Clin Infect Dis 2000; 30:313-318.
314. Kempf DJ, Rode RA, Xu Y, Sun E, Heath-Chiozzi ME, Valdes J, Japour AJ, Danner S, Boucher C, Molla A, Leonard JM. The duration of viral suppression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV-1 RNA at the nadir. AIDS 1998; 12:F9-F14.
315. Lorenzi P, Opravil M, Hirschel B, Chave JP, Furrer HJ, Sax H, Perneger TV, Perrin L, Kaiser L, Yerly S. Impact of drug resistance mutations on virologic response to salvage therapy. Swiss HIV Cohort Study. AIDS 1999; 13:F17-F21.
316. Picchio GR, Valdez H, Sabbe R, Landay AL, Kuritzkes DR, Lederman MM, Mosier DE. Altered viral fitness of HIV-1 following failure of protease-inhibitor-based therapy. J Acq Imm Def Synd 2000; 25:289-295.
317. Schapiro JM, Winters MA, Lawrence J, Merigan TC. Clinical cross-resistance between the HIV-1 protease inhibitors saquinavir and indinavir and correlations with genotypic mutations. AIDS 1999; 13:359-365.
318. Rusconi S, La Seta Catamancio S, Citterio P, Kurtagic S, Violin M, Balotta C, Moroni M, Galli M, D'Arminio-Monforte A. Susceptibility to PNU-140690 (Tipranavir) of human immunodeficiency virus type 1 isolates derived from patients with multidrug resistance to other protease inhibitors. Antimicrob Agents Chemother 2000; 44:1328-1332.
319. Palmer S, Shafer RW, Merigan TC. Highly drug-resistant HIV-1 clinical isolates are cross-resistant to many antiretroviral compounds in current clinical development. AIDS 1999; 13:661-667.
320. Gu Z, Wainberg MA, Nguyen-Ba N, L'Heureux L, de Muys JM, Bowlin TL, Rando RF. Mechanism of action and in vitro activity of 1′,3′ -dioxolanyl-purine nucleoside analogues against sensitive and drug-resistant human immunodeficiency virus type 1 variants. Antimicrob Agents Chemother 1999; 43:2376-2382.
321. Khanna N, Klimkait T, Schiffer V, Irigoyen J, Telenti A, Hirschel B, Battegay M. Salvage therapy with abacavir plus a non-nucleoside reverse transcriptase inhibitor and a protease inhibitor in heavily pretreated HIV-1 infected patients. Swiss HIV Cohort Study. AIDS 2000; 14:791-799.
322. De Mendoza C, Soriano V, Perez-Olmeda M, Rodes B, Casas E, Gonzalez-Lahoz J. Different outcomes in patients achieving complete or partial viral load suppression on antiretroviral therapy. J Hum Virol 1999; 2:344-349.
323. Balotta C, Violin M, Monno L, Bagnarelli P, Riva C, Facchi G, Berlusconi A, Lippi M, Rusconi S, Clementi M, Galli M, Angarano G, Moroni M. Prevalence of multiple dideoxynucleoside analogue resistance (MddNR) in a multicenter cohort of HIV-1-infected Italian patients with virologic failure. J Acquir Immune Defic Syndr 2000; 24: 232-240.
324. Balotta C, Berlusconi A, Pan A, Violin M, Riva C, Colombo MC, Gori A, Papagno L, Corvasce S, Mazzucchelli R, Facchi G, Velleca R, Saporetti G, Galli M, Rusconi S, Moroni M. Prevalence of transmitted nucleoside analogue-resistant HIV-1 strains and pre-existing mutations in pol reverse transcriptase and protease region: outcome after treatment in recently infected individuals. Antiviral Ther 2000; 5:7-14.
325. Balotta, C., Berlusconi A, Pan A, Violin M, Riva C, Gori A, Corvasce S, Mazzucchelli R, Facchi G, Velleca R, Senese D, Deho L, Galli M, Rusconi S, Moroni M. Prevalence of HIV-1 resistant strains in recent seroconverters. J Biol Regul Homeost Agents 2000; 14:51-57.
326. Schmit JC, Van Laethem K, Ruiz L, Hermans P, Sprecher S, Sonnerborg A, Leal M, Harrer T, Clotet B, Arendt V, Lissen E, Witvrouw M, Desmyter J, De Clercq E, Vandamme AM. Multiple dideoxynucleoside analogue-resistant (MddNR) HIV-1 strains isolated from patients from different European countries. AIDS 1998; 12:2007-2015.
327. Boden D, Hurley, A, Zhang L, Cao Y, Guo Y, Jones E, Tsay J, Ip J, Farthing C, Limoli K, Parkin N, Markowitz M. HIV-1 drug resistance in newly infested individuals [see comments]. JAMA 1999; 282:1135-1141.
328. Bossi P, Mouroux M, Yvon A, Bricaire F, Agut H, Huraux JM, Katlama C, Calvez V. Polymorphism of the human immunodeficiency virus type 1 (HIV-1) protease gene and response of HIV-1-infected patients to a protease inhibitor. J Clin Microbiol 1999; 37:2910-2912.
329. Mouroux M, Bossi P, Yvon-Groussin A, Delaugerre C, Valantin MA, Tubiana R, Coutellie A, Bonmarchand M, Bricaire F, Katlama C, Agut H, Huraux JM, Calvez V. [Polymorphism of protease genes in patients infected with HIV-1 and response to therapy including a protease inhibitor]. Pathol Biol (Paris) 1999; 47:549-552.
330. Kuritzkes DR, Sevin A, Young B, Bakhtiari M, Wu H, St Clair M, Connick E, Landay A, Spritzler J, Kessler H, Lederman MM. Effect of zidovudine resistance mutations on virologic response to treatment with zidovudine-lamivudine-ritonavir: genotypic analysis of human immunodeficiency virus type 1 isolates from AIDS clinical trials group protocol 315. ACTG Protocol 315 Team. J Infect Dis 2000; 181:491-497.
331. Havlir DV, Bassett R, Levitan D, Gilbert P, Tebas P, Collier AC, Hirsch MS, Ignacio C, Condra J, Guenthard HF, Richman DD, Wong JK. Prevalence and predictive value of intermittent viremia with combination HIV therapy. JAMA 2001; 286:171-179.
332. Patarca R, Hasseltine WA. Similarities among retrovirus proteins. Nature 1984; 312:496.
333. Benhamou Y, Bochet M, Thibault V, Di Martino V, Caumes E, Bricaire F, Opolon P, Katlama C, Poynard T Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients [see comments]. Hepatology 1999; 30:1302-1306.
334. Koff WC, Elm JL Jr, Halstead SB. Antiviral effects of ribavirin and 6-mercapto-9-tetrahydro-2-furylpurine against dengue viruses in vitro. Antivir Res 1982; 2:69-79.
335. De Vincenzo J. Prevention and treatment of respiratory syncytial virus infections. Adv Ped Infect Dis 1997; 13:1-47.
336. Gubareva LV, Kaiser L, Hayden FG. Influenza virus neuraminidase inhibitor. Lancet 2000; 355: 827-835.
337. Monto AS, Fleming DM, Henry D, de Groot R, Makela M, Klein T, Elliott M, Keene ON, Man CY. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza A and B virus infections. J Infect Dis 1999; 180:256-261.
338. Blaser MJ. The changing relationships of Helicobacter pylori and humans: implications for health and disease. J Infect Dis 1999; 179:1523-1530.
339. Hadley SK, Petry JJ. Medicinal herbs: a primer for primary care. Hosp Practice 1999; 34:105-123.